(RTTNews) - Genmab (GMAB) reported updated Phase 2 data showing that Petosemtamab, when combined with standard chemotherapy, continued to demonstrate encouraging response rates in patients with metastatic colorectal cancer (mCRC). The findings were presented at the ESMO Congress